cancer immunotherapy
Oncology/ Views & Analysis/ Views and analysis/ Webinars/ Webinars in home page/ Webinars On demand
Oncology treatment decisions aren’t just based on clinical data
mike.hammerton@pharmaphorum.com
Brand marketing, cancer immunotherapy, Cerner Enviza, oncology research
0 Comment
German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy
Catherine Longworth
cancer, cancer immunotherapy, CatylYm, financing, Oncology
0 Comment
News/ News/ Oncology/ Top stories
Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China
Richard Staines
cancer immunotherapy, CStone, Pfizer
0 Comment
Oncology/ Views & Analysis/ Views and analysis/ White Papers/ Whitepapers
Preparing for the next decade of innovation in immuno-oncology
mike.smith@pharmaphorum.com
Advanced Clinical, cancer, cancer immunotherapy, immuno-oncology, Oncology, personalised medicine
0 Comment
Gilead poaches oncology expert Quigley from BMS
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, CAR T, Gilead, Kite, R&D
0 Comment
AZ joins with Seres to research role of gut microbiome in cancer
Richard Staines
AstraZeneca, cancer, cancer immunotherapy, gastrointestinal, Seres Therapeutics
0 Comment
News/ News/ Oncology/ Top stories
Keytruda could get patient-friendly 6 week dosing schedule in EU
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co
0 Comment
Celgene signs brace of immuno-oncology deals with US biotechs
Phil Taylor
cancer immunotherapy, Celgene, Kyn Therapeutics, Obsidian Therapeutics
0 Comment